MEP7609A - Therapeutic agent for diabetes - Google Patents

Therapeutic agent for diabetes

Info

Publication number
MEP7609A
MEP7609A MEP-76/09A MEP7609A MEP7609A ME P7609 A MEP7609 A ME P7609A ME P7609 A MEP7609 A ME P7609A ME P7609 A MEP7609 A ME P7609A
Authority
ME
Montenegro
Prior art keywords
diabetes
therapeutic agent
symbol
salt
formula
Prior art date
Application number
MEP-76/09A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Koji Takeuchi
Yusuke Moritoh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP7609A publication Critical patent/MEP7609A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-76/09A 2005-12-28 2006-12-27 Therapeutic agent for diabetes MEP7609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005379407 2005-12-28
JP2006061722 2006-03-07
PCT/JP2006/326141 WO2007074884A1 (ja) 2005-12-28 2006-12-27 糖尿病治療剤

Publications (1)

Publication Number Publication Date
MEP7609A true MEP7609A (en) 2011-12-20

Family

ID=38218106

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-76/09A MEP7609A (en) 2005-12-28 2006-12-27 Therapeutic agent for diabetes

Country Status (16)

Country Link
US (1) US20090042863A1 (xx)
EP (1) EP1970063A4 (xx)
JP (1) JP5094416B2 (xx)
KR (1) KR20080081354A (xx)
AU (1) AU2006330332B2 (xx)
BR (1) BRPI0620718A2 (xx)
CA (1) CA2635777A1 (xx)
GE (1) GEP20105033B (xx)
IL (1) IL192369A0 (xx)
MA (1) MA30176B1 (xx)
ME (1) MEP7609A (xx)
MY (1) MY152172A (xx)
NO (1) NO20083026L (xx)
NZ (1) NZ569661A (xx)
RU (1) RU2438671C2 (xx)
WO (1) WO2007074884A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95828C2 (ru) * 2007-02-01 2011-09-12 Такеда Фармасьютикал Компани Лимитед Твердая рецептура, которая содержит алоглиптин и пиоглитазон
EP2185138B1 (en) * 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
KR101607081B1 (ko) * 2008-05-14 2016-03-29 가부시키가이샤산와카가쿠켄큐쇼 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009281122C1 (en) 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
EP2379522B1 (en) * 2008-12-23 2018-02-28 Sandoz AG Crystalline form of alogliptin
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011079778A1 (en) 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EA027324B1 (ru) 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
DK1228067T3 (da) 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
BRPI0107715B8 (pt) * 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANIN CONCENTRATION HORMONE ANTAGONIST
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070259927A1 (en) * 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
MY152172A (en) 2014-08-15
WO2007074884A1 (ja) 2007-07-05
BRPI0620718A2 (pt) 2011-11-22
IL192369A0 (en) 2011-08-01
AU2006330332B2 (en) 2012-03-08
RU2008130878A (ru) 2010-02-10
CA2635777A1 (en) 2007-07-05
KR20080081354A (ko) 2008-09-09
NZ569661A (en) 2011-06-30
EP1970063A4 (en) 2014-05-21
NO20083026L (no) 2008-09-16
RU2438671C2 (ru) 2012-01-10
US20090042863A1 (en) 2009-02-12
GEP20105033B (en) 2010-06-25
JPWO2007074884A1 (ja) 2009-06-04
MA30176B1 (fr) 2009-01-02
JP5094416B2 (ja) 2012-12-12
AU2006330332A1 (en) 2007-07-05
EP1970063A1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
MEP7609A (en) Therapeutic agent for diabetes
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
MX2010001784A (es) Activadores novedosos de la glucocinasa.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
DK1973541T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
UY30659A1 (es) Grupo de compuestos de benzoilamino heterociclico, composiciones farmacéuticas, porcesos para su preparacion y aplicaciones.
MX2010009736A (es) Compuesto heterociclico.
GEP20115359B (en) Fused cyclic compounds
PE20120330A1 (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1131978A1 (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof
BRPI0510411A (pt) derivados de dióxido de oxazol-benzoisotiazol, processos para a sua fabricação e seu uso
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
RS52629B (en) LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter